- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| Do | Bristol Myers delays Cobenfy Alzheimer's psychosis readout again amid another quarterly beat | ||
| Do | RFK Jr.'s Gardasil litigation ties subject to fresh lawmaker scrutiny after Merck settlement | ||
| Do | Viatris runs into FDA roadblock after advertising on-the-go use of cystic fibrosis inhaler | ||
| Mi | Biogen flips '26 guidance from expected decline to sales increase | ||
| Mi | Boosted by CMS settlement, Incyte expects Opzelura to cross $1B in 2026 | ||
| Mi | Teva's innovation engine offsets generics slump, leaving one analyst 'shocked' by Ajovy's surge | ||
| Mi | PMCPA sanctions melatonin drugmaker over misleading information | ||
| 28.07. | How 2 FDA citations complicate Hengrui, Elevar's push for liver cancer combo approval | ||
| 28.07. | With $5.5B settlement offer, J&J could be on its way to resolving talc litigation | ||
| 28.07. | Baxter issues recall of antibiotic IV bags after bits of cardboard flagged in solution | ||
| 28.07. | GSK CEO targets $2.5B in cost savings from mature products, procurement, supply chain | ||
| 28.07. | Havas Lynx revamps New York C-suite 16 months after last shakeup | ||
| 27.07. | FDA approves Otsuka's ADHD drug Simtriyo, teeing up its 'next major CNS launch' | ||
| 27.07. | On 4th try, Outlook Therapeutics scores FDA nod for reformulated version of Roche's Avastin for AMD | ||
| 27.07. | Sarepta taps AbbVie, Tessera vet Severino to write Duchenne firm's next chapter | ||
| 27.07. | AstraZeneca stays on track for $80B revenue goal as cancer meds, rare disease sales help offset Ultomiris miss | ||
| 27.07. | Legend Biotech CEO abruptly steps down without permanent replacement | ||
| 24.07. | Gastroenterologists flag clinical remission and its durability as unmet needs in IBD care: survey | ||
| 24.07. | Peptide adcomm Day 2: Emideltide voted down in panel's 1st pushback | ||
| 24.07. | Novo escalates Lilly false advertising suit with planned bid to halt comparative ads | ||
| 24.07. | Another setback for Ipsen's Albireo portfolio as Bylvay flunks phase 3 trial | ||
| 24.07. | Amgen hands in data package in hopes of FDA hearing for Tavneos defense | ||
| 24.07. | Merck stages expanded access to monthly HIV PrEP pill ahead of approval | ||
| 24.07. | GSK's first lung cancer approval, a new IPO path and more | ||
| 23.07. | In FDA compounding adcomm, advisers urge against restrictions on 1st of 7 peptides |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.